The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Biosimilar Monoclonal Antibodies Market Research Report 2025
Synopsis
The global market for Biosimilar Monoclonal Antibodies was valued at US$ 6087 million in the year 2024 and is projected to reach a revised size of US$ 16970 million by 2031, growing at a CAGR of 16.0% during the forecast period.
Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies. Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.
The biosimilar monoclonal antibodies market is primarily driven by the increasing demand for cost-effective biologic treatments. As patents for many original biologic drugs expire, biosimilars offer a more affordable alternative without compromising efficacy. This is particularly important in treating chronic diseases like cancer and autoimmune disorders, where long-term treatment costs can be prohibitive. The growing acceptance of biosimilars by healthcare providers and regulatory approvals in various regions further propels market growth. However, a key challenge facing the market is the complexity of manufacturing biosimilar monoclonal antibodies. Due to their structural intricacies, even minor variations in production processes can lead to differences in efficacy or safety compared to the original biologic. Additionally, patient and physician skepticism, driven by concerns over efficacy and potential side effects, can hinder widespread adoption, especially in markets where the original biologics are well-established. Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis, etc. Global top four manufacturers hold a share nearly 85%. Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent. In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biosimilar Monoclonal Antibodies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Monoclonal Antibodies.
The Biosimilar Monoclonal Antibodies market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Biosimilar Monoclonal Antibodies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar Monoclonal Antibodies manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Celltrion
Pfizer (Hospira)
3SBIO
Novartis (Sandoz)
Dr Reddy’s
Celgen Biopharma
Cadila Healthcare
Hisun Pharma
Torrent Pharmaceuticals
Fresenius Kabi
Coherus Solutions
Biogen
Amgen
Biocon Biologics
Organon
Segment by Type
Infliximab
Rituximab
Trastuzumab
Adalimumab
Other
Segment by Application
Oncology
Autoimmune Disease
Other
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Biosimilar Monoclonal Antibodies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Biosimilar Monoclonal Antibodies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global market for Biosimilar Monoclonal Antibodies was valued at US$ 6087 million in the year 2024 and is projected to reach a revised size of US$ 16970 million by 2031, growing at a CAGR of 16.0% during the forecast period.
Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies. Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.
The biosimilar monoclonal antibodies market is primarily driven by the increasing demand for cost-effective biologic treatments. As patents for many original biologic drugs expire, biosimilars offer a more affordable alternative without compromising efficacy. This is particularly important in treating chronic diseases like cancer and autoimmune disorders, where long-term treatment costs can be prohibitive. The growing acceptance of biosimilars by healthcare providers and regulatory approvals in various regions further propels market growth. However, a key challenge facing the market is the complexity of manufacturing biosimilar monoclonal antibodies. Due to their structural intricacies, even minor variations in production processes can lead to differences in efficacy or safety compared to the original biologic. Additionally, patient and physician skepticism, driven by concerns over efficacy and potential side effects, can hinder widespread adoption, especially in markets where the original biologics are well-established. Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis, etc. Global top four manufacturers hold a share nearly 85%. Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent. In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Biosimilar Monoclonal Antibodies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Monoclonal Antibodies.
The Biosimilar Monoclonal Antibodies market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Biosimilar Monoclonal Antibodies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar Monoclonal Antibodies manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Celltrion
Pfizer (Hospira)
3SBIO
Novartis (Sandoz)
Dr Reddy’s
Celgen Biopharma
Cadila Healthcare
Hisun Pharma
Torrent Pharmaceuticals
Fresenius Kabi
Coherus Solutions
Biogen
Amgen
Biocon Biologics
Organon
Segment by Type
Infliximab
Rituximab
Trastuzumab
Adalimumab
Other
Segment by Application
Oncology
Autoimmune Disease
Other
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Biosimilar Monoclonal Antibodies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Biosimilar Monoclonal Antibodies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Biosimilar Monoclonal Antibodies Market Overview
1.1 Product Definition
1.2 Biosimilar Monoclonal Antibodies by Type
1.2.1 Global Biosimilar Monoclonal Antibodies Market Value Comparison by Type (2024 VS 2031)
1.2.2 Infliximab
1.2.3 Rituximab
1.2.4 Trastuzumab
1.2.5 Adalimumab
1.2.6 Other
1.3 Biosimilar Monoclonal Antibodies by Application
1.3.1 Global Biosimilar Monoclonal Antibodies Market Value by Application (2024 VS 2031)
1.3.2 Oncology
1.3.3 Autoimmune Disease
1.3.4 Other
1.4 Global Biosimilar Monoclonal Antibodies Market Size Estimates and Forecasts
1.4.1 Global Biosimilar Monoclonal Antibodies Revenue 2020-2031
1.4.2 Global Biosimilar Monoclonal Antibodies Sales 2020-2031
1.4.3 Global Biosimilar Monoclonal Antibodies Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Biosimilar Monoclonal Antibodies Market Competition by Manufacturers
2.1 Global Biosimilar Monoclonal Antibodies Sales Market Share by Manufacturers (2020-2025)
2.2 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Biosimilar Monoclonal Antibodies Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Biosimilar Monoclonal Antibodies, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Biosimilar Monoclonal Antibodies, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Biosimilar Monoclonal Antibodies, Product Type & Application
2.7 Global Key Manufacturers of Biosimilar Monoclonal Antibodies, Date of Enter into This Industry
2.8 Global Biosimilar Monoclonal Antibodies Market Competitive Situation and Trends
2.8.1 Global Biosimilar Monoclonal Antibodies Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Biosimilar Monoclonal Antibodies Players Market Share by Revenue
2.8.3 Global Biosimilar Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Biosimilar Monoclonal Antibodies Market Scenario by Region
3.1 Global Biosimilar Monoclonal Antibodies Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Biosimilar Monoclonal Antibodies Sales by Region: 2020-2031
3.2.1 Global Biosimilar Monoclonal Antibodies Sales by Region: 2020-2025
3.2.2 Global Biosimilar Monoclonal Antibodies Sales by Region: 2026-2031
3.3 Global Biosimilar Monoclonal Antibodies Revenue by Region: 2020-2031
3.3.1 Global Biosimilar Monoclonal Antibodies Revenue by Region: 2020-2025
3.3.2 Global Biosimilar Monoclonal Antibodies Revenue by Region: 2026-2031
3.4 North America Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
3.4.1 North America Biosimilar Monoclonal Antibodies Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Biosimilar Monoclonal Antibodies Sales by Country (2020-2031)
3.4.3 North America Biosimilar Monoclonal Antibodies Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
3.5.1 Europe Biosimilar Monoclonal Antibodies Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Biosimilar Monoclonal Antibodies Sales by Country (2020-2031)
3.5.3 Europe Biosimilar Monoclonal Antibodies Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Biosimilar Monoclonal Antibodies Market Facts & Figures by Region
3.6.1 Asia Pacific Biosimilar Monoclonal Antibodies Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Biosimilar Monoclonal Antibodies Sales by Region (2020-2031)
3.6.3 Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
3.7.1 Latin America Biosimilar Monoclonal Antibodies Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Biosimilar Monoclonal Antibodies Sales by Country (2020-2031)
3.7.3 Latin America Biosimilar Monoclonal Antibodies Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Biosimilar Monoclonal Antibodies Market Facts & Figures by Country
3.8.1 Middle East and Africa Biosimilar Monoclonal Antibodies Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2020-2031)
3.8.3 Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Biosimilar Monoclonal Antibodies Sales by Type (2020-2031)
4.1.1 Global Biosimilar Monoclonal Antibodies Sales by Type (2020-2025)
4.1.2 Global Biosimilar Monoclonal Antibodies Sales by Type (2026-2031)
4.1.3 Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2020-2031)
4.2 Global Biosimilar Monoclonal Antibodies Revenue by Type (2020-2031)
4.2.1 Global Biosimilar Monoclonal Antibodies Revenue by Type (2020-2025)
4.2.2 Global Biosimilar Monoclonal Antibodies Revenue by Type (2026-2031)
4.2.3 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2020-2031)
4.3 Global Biosimilar Monoclonal Antibodies Price by Type (2020-2031)
5 Segment by Application
5.1 Global Biosimilar Monoclonal Antibodies Sales by Application (2020-2031)
5.1.1 Global Biosimilar Monoclonal Antibodies Sales by Application (2020-2025)
5.1.2 Global Biosimilar Monoclonal Antibodies Sales by Application (2026-2031)
5.1.3 Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2020-2031)
5.2 Global Biosimilar Monoclonal Antibodies Revenue by Application (2020-2031)
5.2.1 Global Biosimilar Monoclonal Antibodies Revenue by Application (2020-2025)
5.2.2 Global Biosimilar Monoclonal Antibodies Revenue by Application (2026-2031)
5.2.3 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2020-2031)
5.3 Global Biosimilar Monoclonal Antibodies Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Celltrion
6.1.1 Celltrion Company Information
6.1.2 Celltrion Description and Business Overview
6.1.3 Celltrion Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Celltrion Biosimilar Monoclonal Antibodies Product Portfolio
6.1.5 Celltrion Recent Developments/Updates
6.2 Pfizer (Hospira)
6.2.1 Pfizer (Hospira) Company Information
6.2.2 Pfizer (Hospira) Description and Business Overview
6.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Portfolio
6.2.5 Pfizer (Hospira) Recent Developments/Updates
6.3 3SBIO
6.3.1 3SBIO Company Information
6.3.2 3SBIO Description and Business Overview
6.3.3 3SBIO Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.3.4 3SBIO Biosimilar Monoclonal Antibodies Product Portfolio
6.3.5 3SBIO Recent Developments/Updates
6.4 Novartis (Sandoz)
6.4.1 Novartis (Sandoz) Company Information
6.4.2 Novartis (Sandoz) Description and Business Overview
6.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Portfolio
6.4.5 Novartis (Sandoz) Recent Developments/Updates
6.5 Dr Reddy’s
6.5.1 Dr Reddy’s Company Information
6.5.2 Dr Reddy’s Description and Business Overview
6.5.3 Dr Reddy’s Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Dr Reddy’s Biosimilar Monoclonal Antibodies Product Portfolio
6.5.5 Dr Reddy’s Recent Developments/Updates
6.6 Celgen Biopharma
6.6.1 Celgen Biopharma Company Information
6.6.2 Celgen Biopharma Description and Business Overview
6.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Product Portfolio
6.6.5 Celgen Biopharma Recent Developments/Updates
6.7 Cadila Healthcare
6.7.1 Cadila Healthcare Company Information
6.7.2 Cadila Healthcare Description and Business Overview
6.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Product Portfolio
6.7.5 Cadila Healthcare Recent Developments/Updates
6.8 Hisun Pharma
6.8.1 Hisun Pharma Company Information
6.8.2 Hisun Pharma Description and Business Overview
6.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Hisun Pharma Biosimilar Monoclonal Antibodies Product Portfolio
6.8.5 Hisun Pharma Recent Developments/Updates
6.9 Torrent Pharmaceuticals
6.9.1 Torrent Pharmaceuticals Company Information
6.9.2 Torrent Pharmaceuticals Description and Business Overview
6.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Portfolio
6.9.5 Torrent Pharmaceuticals Recent Developments/Updates
6.10 Fresenius Kabi
6.10.1 Fresenius Kabi Company Information
6.10.2 Fresenius Kabi Description and Business Overview
6.10.3 Fresenius Kabi Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Fresenius Kabi Biosimilar Monoclonal Antibodies Product Portfolio
6.10.5 Fresenius Kabi Recent Developments/Updates
6.11 Coherus Solutions
6.11.1 Coherus Solutions Company Information
6.11.2 Coherus Solutions Description and Business Overview
6.11.3 Coherus Solutions Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Coherus Solutions Biosimilar Monoclonal Antibodies Product Portfolio
6.11.5 Coherus Solutions Recent Developments/Updates
6.12 Biogen
6.12.1 Biogen Company Information
6.12.2 Biogen Description and Business Overview
6.12.3 Biogen Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Biogen Biosimilar Monoclonal Antibodies Product Portfolio
6.12.5 Biogen Recent Developments/Updates
6.13 Amgen
6.13.1 Amgen Company Information
6.13.2 Amgen Description and Business Overview
6.13.3 Amgen Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Amgen Biosimilar Monoclonal Antibodies Product Portfolio
6.13.5 Amgen Recent Developments/Updates
6.14 Biocon Biologics
6.14.1 Biocon Biologics Company Information
6.14.2 Biocon Biologics Description and Business Overview
6.14.3 Biocon Biologics Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Biocon Biologics Biosimilar Monoclonal Antibodies Product Portfolio
6.14.5 Biocon Biologics Recent Developments/Updates
6.15 Organon
6.15.1 Organon Company Information
6.15.2 Organon Description and Business Overview
6.15.3 Organon Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Organon Biosimilar Monoclonal Antibodies Product Portfolio
6.15.5 Organon Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Biosimilar Monoclonal Antibodies Industry Chain Analysis
7.2 Biosimilar Monoclonal Antibodies Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Biosimilar Monoclonal Antibodies Production Mode & Process Analysis
7.4 Biosimilar Monoclonal Antibodies Sales and Marketing
7.4.1 Biosimilar Monoclonal Antibodies Sales Channels
7.4.2 Biosimilar Monoclonal Antibodies Distributors
7.5 Biosimilar Monoclonal Antibodies Customer Analysis
8 Biosimilar Monoclonal Antibodies Market Dynamics
8.1 Biosimilar Monoclonal Antibodies Industry Trends
8.2 Biosimilar Monoclonal Antibodies Market Drivers
8.3 Biosimilar Monoclonal Antibodies Market Challenges
8.4 Biosimilar Monoclonal Antibodies Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Biosimilar Monoclonal Antibodies Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Biosimilar Monoclonal Antibodies Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Biosimilar Monoclonal Antibodies Market Competitive Situation by Manufacturers in 2024
Table 4. Global Biosimilar Monoclonal Antibodies Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Biosimilar Monoclonal Antibodies Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Biosimilar Monoclonal Antibodies Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Biosimilar Monoclonal Antibodies Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Biosimilar Monoclonal Antibodies Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Biosimilar Monoclonal Antibodies, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Biosimilar Monoclonal Antibodies, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Biosimilar Monoclonal Antibodies, Product Type & Application
Table 12. Global Key Manufacturers of Biosimilar Monoclonal Antibodies, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Biosimilar Monoclonal Antibodies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Monoclonal Antibodies as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Biosimilar Monoclonal Antibodies Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Biosimilar Monoclonal Antibodies Sales by Region (2020-2025) & (K Units)
Table 18. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2020-2025)
Table 19. Global Biosimilar Monoclonal Antibodies Sales by Region (2026-2031) & (K Units)
Table 20. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2026-2031)
Table 21. Global Biosimilar Monoclonal Antibodies Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2020-2025)
Table 23. Global Biosimilar Monoclonal Antibodies Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2026-2031)
Table 25. North America Biosimilar Monoclonal Antibodies Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Biosimilar Monoclonal Antibodies Sales by Country (2020-2025) & (K Units)
Table 27. North America Biosimilar Monoclonal Antibodies Sales by Country (2026-2031) & (K Units)
Table 28. North America Biosimilar Monoclonal Antibodies Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Biosimilar Monoclonal Antibodies Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Biosimilar Monoclonal Antibodies Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Biosimilar Monoclonal Antibodies Sales by Country (2020-2025) & (K Units)
Table 32. Europe Biosimilar Monoclonal Antibodies Sales by Country (2026-2031) & (K Units)
Table 33. Europe Biosimilar Monoclonal Antibodies Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Biosimilar Monoclonal Antibodies Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Biosimilar Monoclonal Antibodies Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Biosimilar Monoclonal Antibodies Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Biosimilar Monoclonal Antibodies Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Biosimilar Monoclonal Antibodies Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Biosimilar Monoclonal Antibodies Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Biosimilar Monoclonal Antibodies Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Biosimilar Monoclonal Antibodies Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Biosimilar Monoclonal Antibodies Sales (K Units) by Type (2020-2025)
Table 51. Global Biosimilar Monoclonal Antibodies Sales (K Units) by Type (2026-2031)
Table 52. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2020-2025)
Table 53. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2026-2031)
Table 54. Global Biosimilar Monoclonal Antibodies Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Biosimilar Monoclonal Antibodies Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2020-2025)
Table 57. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2026-2031)
Table 58. Global Biosimilar Monoclonal Antibodies Price (US$/Unit) by Type (2020-2025)
Table 59. Global Biosimilar Monoclonal Antibodies Price (US$/Unit) by Type (2026-2031)
Table 60. Global Biosimilar Monoclonal Antibodies Sales (K Units) by Application (2020-2025)
Table 61. Global Biosimilar Monoclonal Antibodies Sales (K Units) by Application (2026-2031)
Table 62. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2020-2025)
Table 63. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2026-2031)
Table 64. Global Biosimilar Monoclonal Antibodies Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Biosimilar Monoclonal Antibodies Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2020-2025)
Table 67. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2026-2031)
Table 68. Global Biosimilar Monoclonal Antibodies Price (US$/Unit) by Application (2020-2025)
Table 69. Global Biosimilar Monoclonal Antibodies Price (US$/Unit) by Application (2026-2031)
Table 70. Celltrion Company Information
Table 71. Celltrion Description and Business Overview
Table 72. Celltrion Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Celltrion Biosimilar Monoclonal Antibodies Product
Table 74. Celltrion Recent Developments/Updates
Table 75. Pfizer (Hospira) Company Information
Table 76. Pfizer (Hospira) Description and Business Overview
Table 77. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product
Table 79. Pfizer (Hospira) Recent Developments/Updates
Table 80. 3SBIO Company Information
Table 81. 3SBIO Description and Business Overview
Table 82. 3SBIO Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. 3SBIO Biosimilar Monoclonal Antibodies Product
Table 84. 3SBIO Recent Developments/Updates
Table 85. Novartis (Sandoz) Company Information
Table 86. Novartis (Sandoz) Description and Business Overview
Table 87. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product
Table 89. Novartis (Sandoz) Recent Developments/Updates
Table 90. Dr Reddy’s Company Information
Table 91. Dr Reddy’s Description and Business Overview
Table 92. Dr Reddy’s Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Dr Reddy’s Biosimilar Monoclonal Antibodies Product
Table 94. Dr Reddy’s Recent Developments/Updates
Table 95. Celgen Biopharma Company Information
Table 96. Celgen Biopharma Description and Business Overview
Table 97. Celgen Biopharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Celgen Biopharma Biosimilar Monoclonal Antibodies Product
Table 99. Celgen Biopharma Recent Developments/Updates
Table 100. Cadila Healthcare Company Information
Table 101. Cadila Healthcare Description and Business Overview
Table 102. Cadila Healthcare Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Cadila Healthcare Biosimilar Monoclonal Antibodies Product
Table 104. Cadila Healthcare Recent Developments/Updates
Table 105. Hisun Pharma Company Information
Table 106. Hisun Pharma Description and Business Overview
Table 107. Hisun Pharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Hisun Pharma Biosimilar Monoclonal Antibodies Product
Table 109. Hisun Pharma Recent Developments/Updates
Table 110. Torrent Pharmaceuticals Company Information
Table 111. Torrent Pharmaceuticals Description and Business Overview
Table 112. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product
Table 114. Torrent Pharmaceuticals Recent Developments/Updates
Table 115. Fresenius Kabi Company Information
Table 116. Fresenius Kabi Description and Business Overview
Table 117. Fresenius Kabi Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Fresenius Kabi Biosimilar Monoclonal Antibodies Product
Table 119. Fresenius Kabi Recent Developments/Updates
Table 120. Coherus Solutions Company Information
Table 121. Coherus Solutions Description and Business Overview
Table 122. Coherus Solutions Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Coherus Solutions Biosimilar Monoclonal Antibodies Product
Table 124. Coherus Solutions Recent Developments/Updates
Table 125. Biogen Company Information
Table 126. Biogen Description and Business Overview
Table 127. Biogen Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Biogen Biosimilar Monoclonal Antibodies Product
Table 129. Biogen Recent Developments/Updates
Table 130. Amgen Company Information
Table 131. Amgen Description and Business Overview
Table 132. Amgen Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. Amgen Biosimilar Monoclonal Antibodies Product
Table 134. Amgen Recent Developments/Updates
Table 135. Biocon Biologics Company Information
Table 136. Biocon Biologics Description and Business Overview
Table 137. Biocon Biologics Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138. Biocon Biologics Biosimilar Monoclonal Antibodies Product
Table 139. Biocon Biologics Recent Developments/Updates
Table 140. Organon Company Information
Table 141. Organon Description and Business Overview
Table 142. Organon Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 143. Organon Biosimilar Monoclonal Antibodies Product
Table 144. Organon Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Biosimilar Monoclonal Antibodies Distributors List
Table 148. Biosimilar Monoclonal Antibodies Customers List
Table 149. Biosimilar Monoclonal Antibodies Market Trends
Table 150. Biosimilar Monoclonal Antibodies Market Drivers
Table 151. Biosimilar Monoclonal Antibodies Market Challenges
Table 152. Biosimilar Monoclonal Antibodies Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
Table 156. Authors List of This Report
List of Figures
Figure 1. Product Picture of Biosimilar Monoclonal Antibodies
Figure 2. Global Biosimilar Monoclonal Antibodies Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Biosimilar Monoclonal Antibodies Market Share by Type: 2024 & 2031
Figure 4. Infliximab Product Picture
Figure 5. Rituximab Product Picture
Figure 6. Trastuzumab Product Picture
Figure 7. Adalimumab Product Picture
Figure 8. Other Product Picture
Figure 9. Global Biosimilar Monoclonal Antibodies Market Value by Application (2020-2031) & (US$ Million)
Figure 10. Global Biosimilar Monoclonal Antibodies Market Share by Application: 2024 & 2031
Figure 11. Oncology
Figure 12. Autoimmune Disease
Figure 13. Other
Figure 14. Global Biosimilar Monoclonal Antibodies Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Biosimilar Monoclonal Antibodies Market Size (2020-2031) & (US$ Million)
Figure 16. Global Biosimilar Monoclonal Antibodies Sales (2020-2031) & (K Units)
Figure 17. Global Biosimilar Monoclonal Antibodies Average Price (US$/Unit) & (2020-2031)
Figure 18. Biosimilar Monoclonal Antibodies Report Years Considered
Figure 19. Biosimilar Monoclonal Antibodies Sales Share by Manufacturers in 2024
Figure 20. Global Biosimilar Monoclonal Antibodies Revenue Share by Manufacturers in 2024
Figure 21. Global 5 and 10 Largest Biosimilar Monoclonal Antibodies Players: Market Share by Revenue in Biosimilar Monoclonal Antibodies in 2024
Figure 22. Biosimilar Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23. Global Biosimilar Monoclonal Antibodies Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 24. North America Biosimilar Monoclonal Antibodies Sales Market Share by Country (2020-2031)
Figure 25. North America Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2020-2031)
Figure 26. U.S. Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Canada Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Europe Biosimilar Monoclonal Antibodies Sales Market Share by Country (2020-2031)
Figure 29. Europe Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2020-2031)
Figure 30. Germany Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. France Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. U.K. Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Italy Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Russia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Asia Pacific Biosimilar Monoclonal Antibodies Sales Market Share by Region (2020-2031)
Figure 36. Asia Pacific Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2020-2031)
Figure 37. China Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. Japan Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. South Korea Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. India Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Australia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Taiwan Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Indonesia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Thailand Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Malaysia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Philippines Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Latin America Biosimilar Monoclonal Antibodies Sales Market Share by Country (2020-2031)
Figure 48. Latin America Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2020-2031)
Figure 49. Mexico Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Brazil Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Argentina Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Middle East and Africa Biosimilar Monoclonal Antibodies Sales Market Share by Country (2020-2031)
Figure 53. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2020-2031)
Figure 54. Turkey Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. Saudi Arabia Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. U.A.E Biosimilar Monoclonal Antibodies Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 57. Global Sales Market Share of Biosimilar Monoclonal Antibodies by Type (2020-2031)
Figure 58. Global Revenue Market Share of Biosimilar Monoclonal Antibodies by Type (2020-2031)
Figure 59. Global Biosimilar Monoclonal Antibodies Price (US$/Unit) by Type (2020-2031)
Figure 60. Global Sales Market Share of Biosimilar Monoclonal Antibodies by Application (2020-2031)
Figure 61. Global Revenue Market Share of Biosimilar Monoclonal Antibodies by Application (2020-2031)
Figure 62. Global Biosimilar Monoclonal Antibodies Price (US$/Unit) by Application (2020-2031)
Figure 63. Biosimilar Monoclonal Antibodies Value Chain
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
